No Data
No Data
WuXi AppTec's WuXi Fund I to Subscribe to Sofinnova Biovelocita II, Sofinnova Crossover II
Selected announcement | S.F. Holding's supply chain and international business revenue increased by about 20% in November; WUXI APPTEC subscribed to a private equity fund in Europe focusing on Biotechnology.
In November, S.F. Holding's total revenue from express logistics, supply chain, and international business was 25.196 billion yuan, a year-on-year increase of 6.73%; WUXI APPTEC plans to invest a total of 20 million euros to subscribe for private equity fund shares.
Express News | WuXi AppTec Says Unit Plans to Subscribe for Shares in Two Private Investment Funds With a Total of 20 Mln Euros
WUXI APPTEC: plans to subscribe to private placement fund shares.
On December 19, Gronhui reported that WUXI APPTEC (603259.SH) announced that its wholly-owned subsidiary WuXiPharmaTechHealthcareFundIL.P. (referred to as "WuXiFundI") plans to subscribe for shares in the fund SOFINNOVABIOVELOCITAIIS.L.P. (referred to as "SofinnovaBiovelocitaII" or "SBVII") as a limited partner, with a subscription amount of 10 million euros (according to the exchange rate announced by the China Forex Trading Center on December 19, 2024).
WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Zhongtai: The implementation of the tenth batch of centralized procurement is expected to accelerate the clearance of generic drugs. Commercial insurance is an important incremental logic in the pharmaceutical Sector.
It is recommended to keep a close eye on the progress and implementation of commercial insurance, as improvements in the payment sector are expected to bring about a significant market trend in the Pharmaceutical Sector, with opportunities for recovery and reversal in hospital pharmaceuticals, diagnostics, and Medical Devices.